article pub med sur masitinib

27 publications répertoriées pubmed pour une molécule qui n'aurait pas d'avenir ?


Et seulement chez l homme !


1.
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J.
Cancer Res. 2013 Jan 15;73(2):539-49. doi: 10.1158/0008-5472.CAN-12-2325. Epub 2012 Oct 29.
PMID: 23108136 [PubMed - indexed for MEDLINE]
Related citations
Select item 22882485
2.
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S, Argyle DJ.
Vet Comp Oncol. 2012 Sep;10(3):163-73. doi: 10.1111/j.1476-5829.2012.00342.x. Review.
PMID: 22882485 [PubMed - indexed for MEDLINE]
Related citations
Select item 22857529
3.
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Airley R.
Future Med Chem. 2012 Jul;4(11):1391-4. doi: 10.4155/fmc.12.81. No abstract available.
PMID: 22857529 [PubMed - indexed for MEDLINE]
Related citations
Select item 22691628
4.
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.
BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.
PMID: 22691628 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 22324351
5.
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.
Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28.
PMID: 22324351 [PubMed - indexed for MEDLINE]
Related citations
Select item 22069175
6.
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ, Zalupski MM.
J Surg Oncol. 2011 Dec;104(:901-6. doi: 10.1002/jso.21872. Review.
PMID: 22069175 [PubMed - indexed for MEDLINE]
Related citations
Select item 22031830
7.
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.
PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.
PMID: 22031830 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 21953477
8.
Stevens-Johnson Syndrome induced by masitinib.
Chaigne B, Lagier L, Aubourg A, de Muret A, Jonville-Bera AP, Machet L, Samimi M.
Acta Derm Venereol. 2012 Mar;92(2):210-2. doi: 10.2340/00015555-1196. No abstract available.
PMID: 21953477 [PubMed - indexed for MEDLINE] Free Article
Related citations
Select item 21669561
9.
[KIT and KIT: from biology to clinical use].
Curtit E, Mansi L, Viel E, Dobi E, Chaigneau L, Nguyen T, Pivot X, Blay JY, Kalbacher E.
Bull Cancer. 2012 Feb 1;99(2):191-7. doi: 10.1684/bdc.2011.1386. French.
PMID: 21669561 [PubMed - indexed for MEDLINE]
Related citations
Select item 21419931
10.
Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD.
Semin Oncol. 2011 Apr;38 Suppl 1:S10-9. doi: 10.1053/j.seminoncol.2011.01.018. Review. Erratum in: Semin Oncol. 2011 Jun;38(3):467.
PMID: 21419931 [PubMed - indexed for MEDLINE]
Related citations
Select item 21150434
11.
Stratified medicine in selecting biologics for the treatment of severe asthma.
Morjaria JB, Proiti M, Polosa R.
Curr Opin Allergy Clin Immunol. 2011 Feb;11(1):58-63. doi: 10.1097/ACI.0b013e3283423245. Review.
PMID: 21150434 [PubMed - indexed for MEDLINE]
Related citations
Select item 21136137
12.
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.
Lassau N, Chami L, Koscielny S, Chebil M, Massard C, Benatsou B, Bidault S, Cioffi A, Blay JY, Le Cesne A.
Invest New Drugs. 2012 Apr;30(2):765-71. doi: 10.1007/s10637-010-9592-2. Epub 2010 Dec 7.
PMID: 21136137 [PubMed - indexed for MEDLINE]
Related citations
Select item 21108325
13.
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.
Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.
PMID: 21108325 [PubMed - indexed for MEDLINE]
Related citations
Select item 20483709
14.
[Focus on GIST management].
Tardieu M, Dômont J, Cioffi A, Bonvalot S, Le Cesne A.
Bull Cancer. 2010 Jun;97(6):723-31. doi: 10.1684/bdc.2010.1127. Review. French.
PMID: 20483709 [PubMed - indexed for MEDLINE] Free Article
Related citations
Select item 20364428
15.
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.
Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8. Epub 2010 Apr 4.
PMID: 20364428 [PubMed - indexed for MEDLINE]
Related citations
Select item 20211560
16.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.
Eur J Cancer. 2010 May;46(:1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.
PMID: 20211560 [PubMed - indexed for MEDLINE]
Related citations
Select item 20209107
17.
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P.
PLoS One. 2010 Mar 4;5(3):e9430. doi: 10.1371/journal.pone.0009430.
PMID: 20209107 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 20140276
18.
Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):661-700.
PMID: 20140276 [PubMed - indexed for MEDLINE]
Related citations
Select item 20026421
19.
The complexity of the complicity of mast cells in cancer.
Nechushtan H.
Int J Biochem Cell Biol. 2010 May;42(5):551-4. doi: 10.1016/j.biocel.2009.12.015. Epub 2009 Dec 22. Review.
PMID: 20026421 [PubMed - indexed for MEDLINE]
Related citations
Select item 19958320
20.
Churg and Strauss vasculitis in the course of masitinib treatment: a first report.
Granel B, Rossi P, Koeppel MC, Hermine O, Charpin D.
Allergy. 2010 Aug;65(:1059-60. doi: 10.1111/j.1398-9995.2009.02273.x. Epub 2009 Dec 3. No abstract available.
PMID: 19958320 [PubMed - indexed for MEDLINE]
Related citations
<< First< PrevPage of 2Next >Last >>
Results: 21 to 27 of 27
Filters activated: Humans Clear all
Select item 19789626
21.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.
PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.
PMID: 19789626 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19664170
22.
More about masitinib.
Walker UA.
Arthritis Res Ther. 2009;11(4):120. doi: 10.1186/ar2734. Epub 2009 Jul 13.
PMID: 19664170 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19614621
23.
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P.
Allergy. 2009 Aug;64(:1194-201. doi: 10.1111/j.1398-9995.2009.02122.x.
PMID: 19614621 [PubMed - indexed for MEDLINE]
Related citations
Select item 19549290
24.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loët X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J.
Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23.
PMID: 19549290 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19541476
25.
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP.
Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21.
PMID: 19541476 [PubMed - indexed for MEDLINE]
Related citations
Select item 18597009
26.
Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51.
PMID: 18597009 [PubMed - indexed for MEDLINE]
Related citations
Select item 18230576
27.
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A, Bui B.
Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Review. French.
PMID: 18230576 [PubMed - indexed for MEDLINE] Free Article
Related citations


Plus de 50
Avec les animaux.


Select item 23609781
1.
Management of Secondary Progressive Multiple Sclerosis: Prophylactic Treatment-Past, Present, and Future Aspects.
Rommer PS, Stüve O.
Curr Treat Options Neurol. 2013 Apr 23. [Epub ahead of print]
PMID: 23609781 [PubMed - as supplied by publisher]
Related citations
Select item 23561333
2.
A model of study for human cancer: Spontaneous occurring tumors in dogs. Biological features and translation for new anticancer therapies.
Ranieri G, Gadaleta CD, Patruno R, Zizzo N, Daidone MG, Hansson MG, Paradiso A, Ribatti D.
Crit Rev Oncol Hematol. 2013 Apr 2. doi:pii: S1040-8428(13)00065-6. 10.1016/j.critrevonc.2013.03.005. [Epub ahead of print]
PMID: 23561333 [PubMed - as supplied by publisher]
Related citations
Select item 23466652
3.
Apoptotic effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine osteosarcoma cells.
Fahey CE, Milner RJ, Kow K, Bacon NJ, Salute ME.
Anticancer Drugs. 2013 Jun;24(5):519-26. doi: 10.1097/CAD.0b013e32836002ba.
PMID: 23466652 [PubMed - in process]
Related citations
Select item 23363222
4.
Masitinib reverses doxorubicin resistance in canine lymphoid cells by inhibiting the function of P-glycoprotein.
Zandvliet M, Teske E, Chapuis T, Fink-Gremmels J, Schrickx JA.
J Vet Pharmacol Ther. 2013 Jan 31. doi: 10.1111/jvp.12039. [Epub ahead of print]
PMID: 23363222 [PubMed - as supplied by publisher]
Related citations
Select item 23331696
5.
Kinase dysfunction and kinase inhibitors.
London CA.
Vet Dermatol. 2013 Feb;24(1):181-7.e39-40. doi: 10.1111/j.1365-3164.2012.01081.x.
PMID: 23331696 [PubMed - in process]
Related citations
Select item 23331686
6.
A systematic review of randomized controlled trials for prevention or treatment of atopic dermatitis in dogs: 2008-2011 update.
Olivry T, Bizikova P.
Vet Dermatol. 2013 Feb;24(1):97-117.e25-6. doi: 10.1111/j.1365-3164.2012.01088.x.
PMID: 23331686 [PubMed - in process]
Related citations
Select item 23198834
7.
Biomarkers and Novel Therapeutic Targets in Gastrointestinal Stromal Tumors (GISTs).
Campanella NC, de Oliveira AT, Scapulatempo-Neto C, Peixoto-Guimarães D, Reis RM.
Recent Pat Anticancer Drug Discov. 2012 Nov 26. [Epub ahead of print]
PMID: 23198834 [PubMed - as supplied by publisher]
Related citations
Select item 23108136
8.
VEGFA-VEGFR pathway blockade inhibits tumor-induced regulatory T-cell proliferation in colorectal cancer.
Terme M, Pernot S, Marcheteau E, Sandoval F, Benhamouda N, Colussi O, Dubreuil O, Carpentier AF, Tartour E, Taieb J.
Cancer Res. 2013 Jan 15;73(2):539-49. doi: 10.1158/0008-5472.CAN-12-2325. Epub 2012 Oct 29.
PMID: 23108136 [PubMed - indexed for MEDLINE]
Related citations
Select item 22882485
9.
Receptor tyrosine kinase inhibitors: molecularly targeted drugs for veterinary cancer therapy.
Bavcar S, Argyle DJ.
Vet Comp Oncol. 2012 Sep;10(3):163-73. doi: 10.1111/j.1476-5829.2012.00342.x. Review.
PMID: 22882485 [PubMed - indexed for MEDLINE]
Related citations
Select item 22857529
10.
Lab reports and cat scans: can veterinary oncology guide our way to new treatments for human cancers?
Airley R.
Future Med Chem. 2012 Jul;4(11):1391-4. doi: 10.4155/fmc.12.81. No abstract available.
PMID: 22857529 [PubMed - indexed for MEDLINE]
Related citations
Select item 22747577
11.
Transcriptome and proteome analysis of tyrosine kinase inhibitor treated canine mast cell tumour cells identifies potentially kit signaling-dependent genes.
Klopfleisch R, Meyer A, Schlieben P, Bondzio A, Weise C, Lenze D, Hummel M, Einspanier R, Gruber AD.
BMC Vet Res. 2012 Jun 29;8:96. doi: 10.1186/1746-6148-8-96.
PMID: 22747577 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 22691628
12.
Masitinib treatment in patients with progressive multiple sclerosis: a randomized pilot study.
Vermersch P, Benrabah R, Schmidt N, Zéphir H, Clavelou P, Vongsouthi C, Dubreuil P, Moussy A, Hermine O.
BMC Neurol. 2012 Jun 12;12:36. doi: 10.1186/1471-2377-12-36.
PMID: 22691628 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 22594682
13.
In vitro effects of the tyrosine kinase inhibitor, masitinib mesylate, on canine hemangiosarcoma cell lines.
Lyles SE, Milner RJ, Kow K, Salute ME.
Vet Comp Oncol. 2012 Sep;10(3):223-35. doi: 10.1111/j.1476-5829.2012.00335.x. Epub 2012 May 18.
PMID: 22594682 [PubMed - indexed for MEDLINE]
Related citations
Select item 22583069
14.
NI-1: a novel canine mastocytoma model for studying drug resistance and IgER-dependent mast cell activation.
Hadzijusufovic E, Peter B, Herrmann H, Rülicke T, Cerny-Reiterer S, Schuch K, Kenner L, Thaiwong T, Yuzbasiyan-Gurkan V, Pickl WF, Willmann M, Valent P.
Allergy. 2012 Jul;67(7):858-68. doi: 10.1111/j.1398-9995.2012.02833.x. Epub 2012 May 15.
PMID: 22583069 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 22487554
15.
The tyrosine kinase inhibitor masitinib blunts airway inflammation and improves associated lung mechanics in a feline model of chronic allergic asthma.
Lee-Fowler TM, Guntur V, Dodam J, Cohn LA, DeClue AE, Reinero CR.
Int Arch Allergy Immunol. 2012;158(4):369-74. doi: 10.1159/000335122. Epub 2012 Apr 4.
PMID: 22487554 [PubMed - indexed for MEDLINE]
Related citations
Select item 22324351
16.
Mast cell leukemia: identification of a new c-Kit mutation, dup(501-502), and response to masitinib, a c-Kit tyrosine kinase inhibitor.
Georgin-Lavialle S, Lhermitte L, Suarez F, Yang Y, Letard S, Hanssens K, Feger F, Renand A, Brouze C, Canioni D, Asnafi V, Chandesris MO, Aouba A, Gineste P, Macintyre E, Mansfield CD, Moussy A, Lepelletier Y, Dubreuil P, Hermine O.
Eur J Haematol. 2012 Jul;89(1):47-52. doi: 10.1111/j.1600-0609.2012.01761.x. Epub 2012 Apr 28.
PMID: 22324351 [PubMed - indexed for MEDLINE]
Related citations
Select item 22236016
17.
Masitinib demonstrates anti-proliferative and pro-apoptotic activity in primary and metastatic feline injection-site sarcoma cells.
Lawrence J, Saba C, Gogal R Jr, Lamberth O, Vandenplas ML, Hurley DJ, Dubreuil P, Hermine O, Dobbin K, Turek M.
Vet Comp Oncol. 2012 Jun;10(2):143-54. doi: 10.1111/j.1476-5829.2011.00291.x. Epub 2011 Aug 25.
PMID: 22236016 [PubMed - indexed for MEDLINE]
Related citations
Select item 22069175
18.
Systemic therapy for advanced gastrointestinal stromal tumors: beyond imatinib.
Kim EJ, Zalupski MM.
J Surg Oncol. 2011 Dec;104(:901-6. doi: 10.1002/jso.21872. Review.
PMID: 22069175 [PubMed - indexed for MEDLINE]
Related citations
Select item 22031830
19.
Depression in patients with mastocytosis: prevalence, features and effects of masitinib therapy.
Moura DS, Sultan S, Georgin-Lavialle S, Pillet N, Montestruc F, Gineste P, Barete S, Damaj G, Moussy A, Lortholary O, Hermine O.
PLoS One. 2011;6(10):e26375. doi: 10.1371/journal.pone.0026375. Epub 2011 Oct 21.
PMID: 22031830 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 21953477
20.
Stevens-Johnson Syndrome induced by masitinib.
Chaigne B, Lagier L, Aubourg A, de Muret A, Jonville-Bera AP, Machet L, Samimi M.
Acta Derm Venereol. 2012 Mar;92(2):210-2. doi: 10.2340/00015555-1196. No abstract available.
PMID: 21953477 [PubMed - indexed for MEDLINE] Free Article
Related citations
Select item 21669561
21.
[KIT and KIT: from biology to clinical use].
Curtit E, Mansi L, Viel E, Dobi E, Chaigneau L, Nguyen T, Pivot X, Blay JY, Kalbacher E.
Bull Cancer. 2012 Feb 1;99(2):191-7. doi: 10.1684/bdc.2011.1386. French.
PMID: 21669561 [PubMed - indexed for MEDLINE]
Related citations
Select item 21668810
22.
Masitinib decreases signs of canine atopic dermatitis: a multicentre, randomized, double-blind, placebo-controlled phase 3 trial.
Cadot P, Hensel P, Bensignor E, Hadjaje C, Marignac G, Beco L, Fontaine J, Jamet JF, Georgescu G, Campbell K, Cannon A, Osborn SC, Messinger L, Gogny-Goubert M, Dubreuil P, Moussy A, Hermine O.
Vet Dermatol. 2011 Dec;22(6):554-64. doi: 10.1111/j.1365-3164.2011.00990.x. Epub 2011 Jun 13.
PMID: 21668810 [PubMed - indexed for MEDLINE]
Related citations
Select item 21504563
23.
Masitinib as an adjunct therapy for mild-to-moderate Alzheimer's disease: a randomised, placebo-controlled phase 2 trial.
Piette F, Belmin J, Vincent H, Schmidt N, Pariel S, Verny M, Marquis C, Mely J, Hugonot-Diener L, Kinet JP, Dubreuil P, Moussy A, Hermine O.
Alzheimers Res Ther. 2011 Apr 19;3(2):16. doi: 10.1186/alzrt75.
PMID: 21504563 [PubMed] Free PMC Article
Related citations
Select item 21480930
24.
Biological effect of tyrosine kinase inhibitors on three canine mast cell tumor cell lines with various KIT statuses.
Takeuchi Y, Fujino Y, Fukushima K, Watanabe M, Nakagawa T, Ohno K, Sasaki N, Sugano S, Tsujimoto H.
J Vet Pharmacol Ther. 2012 Feb;35(1):97-104. doi: 10.1111/j.1365-2885.2011.01296.x. Epub 2011 Apr 12.
PMID: 21480930 [PubMed - indexed for MEDLINE]
Related citations
Select item 21419931
25.
Differential properties of current tyrosine kinase inhibitors in gastrointestinal stromal tumors.
Demetri GD.
Semin Oncol. 2011 Apr;38 Suppl 1:S10-9. doi: 10.1053/j.seminoncol.2011.01.018. Review. Erratum in: Semin Oncol. 2011 Jun;38(3):467.
PMID: 21419931 [PubMed - indexed for MEDLINE]
Related citations
Select item 21333567
26.
Masitinib as a chemosensitizer of canine tumor cell lines: a proof of concept study.
Thamm DH, Rose B, Kow K, Humbert M, Mansfield CD, Moussy A, Hermine O, Dubreuil P.
Vet J. 2012 Jan;191(1):131-4. doi: 10.1016/j.tvjl.2011.01.001. Epub 2011 Feb 17.
PMID: 21333567 [PubMed - indexed for MEDLINE]
Related citations
Select item 21314730
27.
Safety of masitinib mesylate in healthy cats.
Daly M, Sheppard S, Cohen N, Nabity M, Moussy A, Hermine O, Wilson H.
J Vet Intern Med. 2011 Mar-Apr;25(2):297-302. doi: 10.1111/j.1939-1676.2011.0687.x. Epub 2011 Feb 11.
PMID: 21314730 [PubMed - indexed for MEDLINE]
Related citations
Select item 21257519
28.
Clinical trial on the efficacy of masitinib in canine IBD.
Procoli F.
Vet Rec. 2010 Nov 6;167(19):760. doi: 10.1136/vr.c6030. No abstract available.
PMID: 21257519 [PubMed - indexed for MEDLINE]
Related citations
Select item 21150434
29.
Stratified medicine in selecting biologics for the treatment of severe asthma.
Morjaria JB, Proiti M, Polosa R.
Curr Opin Allergy Clin Immunol. 2011 Feb;11(1):58-63. doi: 10.1097/ACI.0b013e3283423245. Review.
PMID: 21150434 [PubMed - indexed for MEDLINE]
Related citations
Select item 21136137
30.
Quantitative functional imaging by dynamic contrast enhanced ultrasonography (DCE-US) in GIST patients treated with masatinib.
Lassau N, Chami L, Koscielny S, Chebil M, Massard C, Benatsou B, Bidault S, Cioffi A, Blay JY, Le Cesne A.
Invest New Drugs. 2012 Apr;30(2):765-71. doi: 10.1007/s10637-010-9592-2. Epub 2010 Dec 7.
PMID: 21136137 [PubMed - indexed for MEDLINE]
Related citations
Select item 21108325
31.
Masitinib for the treatment of systemic and cutaneous mastocytosis with handicap: a phase 2a study.
Paul C, Sans B, Suarez F, Casassus P, Barete S, Lanternier F, Grandpeix-Guyodo C, Dubreuil P, Palmérini F, Mansfield CD, Gineste P, Moussy A, Hermine O, Lortholary O.
Am J Hematol. 2010 Dec;85(12):921-5. doi: 10.1002/ajh.21894.
PMID: 21108325 [PubMed - indexed for MEDLINE]
Related citations
Select item 21034327
32.
Evaluation of 12- and 24-month survival rates after treatment with masitinib in dogs with nonresectable mast cell tumors.
Hahn KA, Legendre AM, Shaw NG, Phillips B, Ogilvie GK, Prescott DM, Atwater SW, Carreras JK, Lana SE, Ladue T, Rusk A, Kinet JP, Dubreuil P, Moussy A, Hermine O.
Am J Vet Res. 2010 Nov;71(11):1354-61. doi: 10.2460/ajvr.71.11.1354. Erratum in: Am J Vet Res. 2011 Feb;72(2):247.
PMID: 21034327 [PubMed - indexed for MEDLINE]
Related citations
Select item 20483709
33.
[Focus on GIST management].
Tardieu M, Dômont J, Cioffi A, Bonvalot S, Le Cesne A.
Bull Cancer. 2010 Jun;97(6):723-31. doi: 10.1684/bdc.2010.1127. Review. French.
PMID: 20483709 [PubMed - indexed for MEDLINE] Free Article
Related citations
Select item 20391634
34.
"Masitinib" is safe and effective for the treatment of canine mast cell tumors.
Gentilini F.
J Vet Intern Med. 2010 Jan-Feb;24(1):6; author reply 7. No abstract available.
PMID: 20391634 [PubMed - indexed for MEDLINE]
Related citations
Select item 20364428
35.
Safety and activity of masitinib in combination with gemcitabine in patients with advanced pancreatic cancer.
Mitry E, Hammel P, Deplanque G, Mornex F, Levy P, Seitz JF, Moussy A, Kinet JP, Hermine O, Rougier P, Raymond E.
Cancer Chemother Pharmacol. 2010 Jul;66(2):395-403. doi: 10.1007/s00280-010-1299-8. Epub 2010 Apr 4.
PMID: 20364428 [PubMed - indexed for MEDLINE]
Related citations
Select item 20211560
36.
Phase II study of oral masitinib mesilate in imatinib-naïve patients with locally advanced or metastatic gastro-intestinal stromal tumour (GIST).
Le Cesne A, Blay JY, Bui BN, Bouché O, Adenis A, Domont J, Cioffi A, Ray-Coquard I, Lassau N, Bonvalot S, Moussy A, Kinet JP, Hermine O.
Eur J Cancer. 2010 May;46(:1344-51. doi: 10.1016/j.ejca.2010.02.014. Epub 2010 Mar 6.
PMID: 20211560 [PubMed - indexed for MEDLINE]
Related citations
Select item 20209107
37.
Masitinib combined with standard gemcitabine chemotherapy: in vitro and in vivo studies in human pancreatic tumour cell lines and ectopic mouse model.
Humbert M, Castéran N, Letard S, Hanssens K, Iovanna J, Finetti P, Bertucci F, Bader T, Mansfield CD, Moussy A, Hermine O, Dubreuil P.
PLoS One. 2010 Mar 4;5(3):e9430. doi: 10.1371/journal.pone.0009430.
PMID: 20209107 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 20140276
38.
Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol. 2009 Dec;31(10):661-700.
PMID: 20140276 [PubMed - indexed for MEDLINE]
Related citations
Select item 20136717
39.
Drug-induced minimal change nephropathy in a dog.
Sum SO, Hensel P, Rios L, Brown S, Howerth EW, Driskell EA, Moussy A, Hermine O, Brown CA.
J Vet Intern Med. 2010 Mar-Apr;24(2):431-5. doi: 10.1111/j.1939-1676.2010.0471.x. No abstract available.
PMID: 20136717 [PubMed - indexed for MEDLINE]
Related citations
Select item 22215315
40.
[New drugs for small animals in 2009].
Emmerich IU.
Tierarztl Prax Ausg K Kleintiere Heimtiere. 2010;38(5):300-12. German.
PMID: 22215315 [PubMed]
Related citations
Select item 20033487
41.
Masitinib for the treatment of canine atopic dermatitis: a pilot study.
Daigle J, Moussy A, Mansfield CD, Hermine O.
Vet Res Commun. 2010 Jan;34(1):51-63. doi: 10.1007/s11259-009-9332-2. Epub 2009 Dec 23.
PMID: 20033487 [PubMed - indexed for MEDLINE]
Related citations
Select item 20026421
42.
The complexity of the complicity of mast cells in cancer.
Nechushtan H.
Int J Biochem Cell Biol. 2010 May;42(5):551-4. doi: 10.1016/j.biocel.2009.12.015. Epub 2009 Dec 22. Review.
PMID: 20026421 [PubMed - indexed for MEDLINE]
Related citations
Select item 19958320
43.
Churg and Strauss vasculitis in the course of masitinib treatment: a first report.
Granel B, Rossi P, Koeppel MC, Hermine O, Charpin D.
Allergy. 2010 Aug;65(:1059-60. doi: 10.1111/j.1398-9995.2009.02273.x. Epub 2009 Dec 3. No abstract available.
PMID: 19958320 [PubMed - indexed for MEDLINE]
Related citations
Select item 19789626
44.
Masitinib (AB1010), a potent and selective tyrosine kinase inhibitor targeting KIT.
Dubreuil P, Letard S, Ciufolini M, Gros L, Humbert M, Castéran N, Borge L, Hajem B, Lermet A, Sippl W, Voisset E, Arock M, Auclair C, Leventhal PS, Mansfield CD, Moussy A, Hermine O.
PLoS One. 2009 Sep 30;4(9):e7258. doi: 10.1371/journal.pone.0007258.
PMID: 19789626 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19732728
45.
Tyrosine kinase inhibitors in veterinary medicine.
London CA.
Top Companion Anim Med. 2009 Aug;24(3):106-12. doi: 10.1053/j.tcam.2009.02.002. Review.
PMID: 19732728 [PubMed - indexed for MEDLINE]
Related citations
Select item 19664170
46.
More about masitinib.
Walker UA.
Arthritis Res Ther. 2009;11(4):120. doi: 10.1186/ar2734. Epub 2009 Jul 13.
PMID: 19664170 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19614621
47.
Masitinib, a c-kit/PDGF receptor tyrosine kinase inhibitor, improves disease control in severe corticosteroid-dependent asthmatics.
Humbert M, de Blay F, Garcia G, Prud'homme A, Leroyer C, Magnan A, Tunon-de-Lara JM, Pison C, Aubier M, Charpin D, Vachier I, Purohit A, Gineste P, Bader T, Moussy A, Hermine O, Chanez P.
Allergy. 2009 Aug;64(:1194-201. doi: 10.1111/j.1398-9995.2009.02122.x.
PMID: 19614621 [PubMed - indexed for MEDLINE]
Related citations
Select item 19549290
48.
Masitinib in the treatment of active rheumatoid arthritis: results of a multicentre, open-label, dose-ranging, phase 2a study.
Tebib J, Mariette X, Bourgeois P, Flipo RM, Gaudin P, Le Loët X, Gineste P, Guy L, Mansfield CD, Moussy A, Dubreuil P, Hermine O, Sibilia J.
Arthritis Res Ther. 2009;11(3):R95. doi: 10.1186/ar2740. Epub 2009 Jun 23.
PMID: 19549290 [PubMed - indexed for MEDLINE] Free PMC Article
Related citations
Select item 19541476
49.
Phase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancers.
Soria JC, Massard C, Magné N, Bader T, Mansfield CD, Blay JY, Bui BN, Moussy A, Hermine O, Armand JP.
Eur J Cancer. 2009 Sep;45(13):2333-41. doi: 10.1016/j.ejca.2009.05.010. Epub 2009 Jun 21.
PMID: 19541476 [PubMed - indexed for MEDLINE]
Related citations
Select item 19533403
50.
Pharmacokinetics of masitinib in cats.
Bellamy F, Bader T, Moussy A, Hermine O.
Vet Res Commun. 2009 Dec;33(:831-7. doi: 10.1007/s11259-009-9231-6.
PMID: 19533403 [PubMed - indexed for MEDLINE]
Related citations
Select item 18823406
51.
Masitinib is safe and effective for the treatment of canine mast cell tumors.
Hahn KA, Ogilvie G, Rusk T, Devauchelle P, Leblanc A, Legendre A, Powers B, Leventhal PS, Kinet JP, Palmerini F, Dubreuil P, Moussy A, Hermine O.
J Vet Intern Med. 2008 Nov-Dec;22(6):1301-9. doi: 10.1111/j.1939-1676.2008.0190.x. Epub 2008 Sep 24. Erratum in: J Vet Intern Med. 2009 Jan-Feb;23(1):224. Oglivie, G [corrected to Ogilvie, G].
PMID: 18823406 [PubMed - indexed for MEDLINE]
Related citations
Select item 18597009
52.
Gateways to clinical trials.
Tomillero A, Moral MA.
Methods Find Exp Clin Pharmacol. 2008 Apr;30(3):231-51.
PMID: 18597009 [PubMed - indexed for MEDLINE]
Related citations
Select item 18230576
53.
[Gastrointestinal stromal tumors: molecular aspects and therapeutic implications].
Italiano A, Bui B.
Bull Cancer. 2008 Jan;95(1):107-16. doi: 10.1684/bdc.2008.0561. Review. French.
PMID: 18230576 [PubMed - indexed for MEDLINE] Free Article
Related citations
recommander